Abstract
Background and aims 1-H nuclear magnetic resonance (1H-NMR) metabolomic measures in plasma have yielded significant insight into the pathophysiology of cardiometabolic disease, but their interrelated nature complicates causal inference and clinical interpretation. This study aimed to investigate the associations of unrelated 1H-NMR metabolomic profiles with coronary artery disease (CAD), type 2 diabetes (T2D) and ischemic stroke (ISTR).
Methods Principal component (PC) analysis was performed on 168 1H-NMR metabolomic measures in 56,712 unrelated European participants from UK Biobank to retrieve unrelated PCs, which were used in multivariable-adjusted cox-proportional hazard models and genome-wide association analyses for Mendelian Randomization (MR). Two-sample MR analyses were conducted in three non-overlapping databases which were subsequently meta-analysed, resulting in combined sample sizes of 755,481 (128,728 cases), 1,017,097 (121,977 cases), and 1,002,264 (56,067 cases) for CAD, T2D, and ISTR, respectively.
Results We identified six PCs which collectively explained 88% of the total variance. For CAD in particular, results from both multivariable-adjusted and MR analyses were generally directionally consistent. The pooled odds ratios (ORs) [95% CI] of per one-SD increase in genetically-influenced PC1 and PC3 (both characterized by distinct ApoB-associated lipoprotein profiles) were 1.04 [1.03, 1.05] and 0.94 [0.93, 0.96], respectively. In addition, the pooled OR for CAD of PC4, characterized by simultaneously decreased small HDL and increased large HDL, and independent of ApoB, was 1.05 [1.03, 1.07]. For the other outcomes, PC5 (characterized by increased amino acids) was associated with a higher risk of T2D and ISTR.
Conclusions This study highlights the existence of an ApoB-independent lipoprotein profile driving CAD. Interestingly, this profile is characterized by a distinctive HDL sub-particle distribution, providing evidence for a role of HDL in the development of CAD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Ms. Ao is supported by the China Scholarship Council (CSC; no. 202106240064). Prof. dr. Jukema and Prof. dr. Rensen are supported by the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation (CVON-GENIUS-2). Dr. Noordam is supported by an innovation grant from the Dutch Heart Foundation (grant number 2019T103).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of North-West Multicenter Research gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.